New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection

Izaskun Buendia, Elisa Navarro, Patrycja Michalska, Isabel Gameiro, Javier Egea, Sheila Abril, Alicia López, Laura González-Lafuente, Manuela G. López, Rafael León

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Background: Neurodegenerative diseases share many pathological pathways, such as abnormal protein aggregation, mitochondrial dysfunction, extensive oxidative stress and neuroinflammation. Cells have an intrinsic mechanism of protection, the Nrf2 transcriptional factor, known as the master regulator of redox homeostasis. Results: Based on the common features of these diseases we have designed a multi-target hybrid structure derived from melatonin and ethyl cinnamate. The obtained derivatives were Nrf2 inducers and potent-free radical scavengers. These new compounds showed a very interesting neuroprotective profile in several in vitro models of oxidative stress, Alzheimer's disease and brain ischemia. Conclusion: We have designed a new hybrid structure with complementary activities. We have identified compound 5h as an interesting Nrf2 inducer, very potent antioxidant and neuroprotectant.

Original languageEnglish
Pages (from-to)1961-1969
Number of pages9
JournalFuture Medicinal Chemistry
Volume7
Issue number15
DOIs
StatePublished - Oct 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection'. Together they form a unique fingerprint.

Cite this